3 3 ABC ® Enabled Mainstay Biologics Target Product Profiles What are the potential implications and upsides for Zenkuda and KSI-501 in DAYBREAK, if successful? ZENKUDA KSI-501 Strong and immediate disease control (closing the ‘immediacy’ gap) Better vision gains vs anti-VEGF mono- therapy (aflibercept Q8W) with good OCT control Non-inferior vision gains to aflibercept Q8W Long-interval dosing with flexible 1-month through 6-month label Not assessed in DAYBREAK